

BARBARA ANN
KARMANOS
CANCER INSTITUTE

June 18, 2008

U.S. Nuclear Regulatory Commission, Region III
Materials Licensing Branch
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352


Re: Request for Authorized User Status for License #21-04127-06

Dear Sir or Madame,

This letter is a request to grant Authorized User Status to Jack Zhenhua Wang, M.D., for 35.400, 35.500 and 35.600 limited to Iridium-192 in a High Dose Rate Remote Afterloading Brachytherapy device. We have attached a copy of the NRC license on which he is named AU, NRC license number 21-04125-01 at Hackley Hospital in Michigan. If you require further assistance please feel free to contact our RSO Joe Rakowski at (313)745-1435.

Thank you.

Sincerely,



Mara Jelich
Manager Ambulatory Operations
Karmanos Cancer Center

RECEIVED JUN 24 2008

2007-07-10 15:54 Washington Hospital, CTC

1(231)728-4062 >>

6305151078 P 10/20

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 5 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number:

21-04125-01

Docket or Reference Number:

030-02044

Amendment No. 75

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
James A. Lieberman, M.D.	10 CFR 35.100 and 35.200.
Michael A. Engel, M.D.	10 CFR 35.100, 35.200 and 35.300.
Theodore Ostermann, M.D.	10 CFR 35.100, 35.200 and 35.300.
Mark E. Meenings, M.D.	10 CFR 35.200.
Ralph Ryan, M.D.	10 CFR 35.200.
Daniel West, M.D.	10 CFR 35.200.
William E. Nall, Jr., M.D.	10 CFR 35.400 and 35.500.
James R. Bos, M.D.	10 CFR 35.100 and 35.200.
John C. Stralner, M.D.	10 CFR 35.100 and 35.200.
Richard A. Wilcox, M.D.	10 CFR 35.100, 35.200 and 35.300.
Gregory A. Bernath, M.D.	10 CFR 35.100 and 35.200.
Thomas J. Hill, M.D.	10 CFR 35.100 and 35.200.
Merk R. Pennington, M.D.	10 CFR 35.100, 35.200 and 35.300.
John D. Kaurich, M.D.	10 CFR 35.100 and 35.200.
Mario Orsini, D.O.	10 CFR 35.100 and 35.200.
Eric Stuart, M.D.	10 CFR 35.100 and 35.200.
Jack Zhenhua Wang, M.D.	10 CFR 35.400, 35.500 and Iridium-192 in a remote afterloading unit.

C. The following individuals are authorized medical physicists as indicated:

Authorized Medical Physicists	Material and Use
David S. Wald, M.S., DABMP	Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, and spot checks.

Official Use Only - Security-Related Information

2007-07-18 11:52 - [illegible] - [illegible]

112311728-4062 >>

6305151078 P 11/20

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 5 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

21-04125-01

Docket or Reference Number

030-02044

Amendment No. 75

Carlo Santa Ana, M.S., DABR

Iridium-192 in a High Dose Rate Remote Afterloader
Unit for calibrations, and spot-checks.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
16. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
 - A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under an Agreement State's Agreement.
 - B. In the absence of a certificate of registration, a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under an Agreement State's Agreement, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use, transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.60(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
 - E. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

Official Use Only - Security-Related Information

BARBARA ANN
KARMANOS
CANCER INSTITUTE

*Detroit Medical Center
Wayne State University*

*In Partnership With
The Detroit Medical Center
Wayne State University
Michigan Cancer Foundation*

*Gershenson Radiation Oncology Center
3990 John R
Detroit, MI 48201*

CERTIFIED MAIL



7003 2260 0004 7174 5158



UNITED STATES POSTAGE
PITNEY BOWLES
02 1A
0004370916
\$ 05.32⁰
JUN 20 2008
MAILED FROM ZIP CODE 48201

U.S. Nuclear Regulatory Commission, Region III
Materials Licensing Branch
2443 Warrenville Rd., Suite 210
Lisle, IL 60532-4352

60532+4352

